



## Robin L. Hansen, M.D.

### Clinical Interests

Robin Hansen, M.D., is Professor of Pediatrics, Director of the UC Davis Center for Excellence in Developmental Disabilities and Director of Clinical programs at the MIND Institute. She is a board-certified developmental behavioral pediatrician with vast experience in treating children with neurodevelopmental disorders as well as in clinical research. She has been the Director of the NICU Follow-up Clinic at UC Davis since 1985.

Her clinical research has focused on children's temperament, long-term effects of prenatal drug exposure, gene-environment interactions related to causes; early identification of autism spectrum disorders, and biomedical treatments for neurodevelopmental disorders.

She is currently a co-investigator on several grants investigating gene-environment interactions and immune dysfunction in autism spectrum disorders (CHARGE, MARBLES and the Autism Phenome Project), responsible for clinical assessment and medical data collection and analysis.

Dr. Hansen is the principal investigator for the Community Outreach and Translation Core of the UC Davis Center for Children's Environmental health, with ties to community agencies and consumers critical for recruitment and information dissemination.

She heads a multidisciplinary clinic that provides international consultant to Uganda and Mexico for establishing developmental screening and clinical assessment services.

**Title** Chief of Child Development and Behavioral Pediatrics  
M.I.N.D. Institute Director of Clinical Programs  
Professor of Pediatrics

**Specialty** Pediatric Child Development & Behavior

**Department** [Pediatrics](#)

**Division** Child Development and Behavior

**Center/Program Affiliation** [Center for Children's Environmental Health](#)  
[UC Davis Children's Hospital](#)  
[UC Davis MIND Institute](#)

**Address/Phone** UC Davis MIND Institute, 2825 50th St. Sacramento, CA 95817



## Robin L. Hansen, M.D.

**Education** M.D., UC Davis School of Medicine, Sacramento, California, 1977  
B.A., Stanford University, Palo Alto, California, 1973

**Residency** Oakland Children's Hospital and Medical Center, Oakland, California, 1977-79

**Fellowships** John F. Kennedy Child Development Center, University of Colorado Health Sciences Center, Denver, Colorado, 1979-81

**Board Certifications** American Board of Pediatrics, 1984  
American Board of Pediatrics, Developmental and Behavioral, 2002

**Select Recent Publications** Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. *Brain Behav Immun.* 2011 Jan;25(1):40-5. Epub 2010 Aug 10.

Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Altered T cell responses in children with autism. *Brain Behav Immun.* 2011 Jul;25(5):840-9. Epub 2010 Sep 15.

Stamova B, Green PG, Tian Y, Hertz-Picciotto I, Pessah IN, Hansen R, Yang X, Teng J, Gregg JP, Ashwood P, Van de Water J, Sharp FR. Correlations between gene expression and mercury levels in blood of boys with and without autism. *Neurotox Res.* 2011 Jan;19(1):31-48. Epub 2009 Nov 24.

Tian Y, Green PG, Stamova B, Hertz-Picciotto I, Pessah IN, Hansen R, Yang X, Gregg JP, Ashwood P, Jickling G, Van de Water J, Sharp FR. Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. *Neurotox Res* Hertz-Picciotto I, Green PG, Delwiche L, Hansen R, Walker C, Pessah IN. Bloo mercury concentrations in CHARGE Study children with and without autism. *Environ Health Perspect.* 2010 Jan;118(1):161-6.

Baker DL, Miller E, Dang MT, Yaangh CS, Hansen RL. Developing culturally responsive approaches with Southeast Asian American families experiencing developmental disabilities. *Pediatrics.* 2010 Dec;126 Suppl 3:S146-50.

Akins RS, Angkustsiri K, Hansen RL. Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families. *Neurotherapeutics.* 2010 Jul;7(3):307-19. Review.

Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, Hertz-Picciotto I, Van de Water JA, Sharp FR, Ashwood P. Altered gene expression and function of peripheral blood natural killer cells in children with autism. *Brain Behav Immun.* 2009 Jan;23(1):124-33. Epub 2008 Aug 14.

Onore C, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, Van de Water J, Ashwood P. Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders. *J Neuroimmunol.* 2009 Nov 30;216(1-2):126-9. Epub 2009 Oct 2.



## Robin L. Hansen, M.D.

Ozonoff S, Heung K, Byrd R, Hansen R, Hertz-Picciotto I. The onset of autism: patterns of symptom emergence in the first years of life. *Autism Res.* 2008 Dec;1(6):320-8.

Jelliffe-Pawlowski LL, Hansen RL. Neurodevelopmental outcome at 8-months and 4-years among infants born full-term small-for-gestational-age. *Journal of Perinatology.* 24, 505-514, 2004.

Nowicki S, Hansen RL, Hagerman, RJ. Fragile X and X linked mental retardation. In A Capute & R Accardo (Eds.) *Developmental Disabilities in Infancy and Childhood*, 2004.

Hansen RL, Hagerman RJ. Fragile X syndrome in adulthood. In CR Reynolds & S Goldstein (Ed.) *Handbook of Neurodevelopmental & Genetic Disorders in Adults*. Guilford Publications, Inc., 2004.

Hansen RL, Lakhani F, Barton K, Metcalf MB, Joye NR. Comparing the health status of low-income children in and out of foster care. *Child Welfare.* 83(4), 367-380, 2004.

© 2017 UC Regents